Agios appoints Tsveta Milanova as CCO effective Jan 3, 2023; Richa Poddar departs Dec 31, 2022

AGIOS PHARMACEUTICALS, INC.

Tsveta Milanova named Chief Commercial Officer, will succeed Richa Poddar effective Jan 3, 2023.
Milanova previously SVP US Commercial at Alexion; brings rare disease commercial launch experience.
Poddar will receive $450K severance plus 2022 target bonus and 12-month COBRA coverage.
Milanova's base salary $510K, target bonus 45%, sign-on bonus $150K, plus equity grants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tsveta Milanova

Chief Commercial Officer

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2023-01-03
Filed: December 6, 2022, 6:59 PM ET

the Company appointed Tsveta Milanova as the Company’s Chief Commercial Officer, effective as of January 3, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tsveta Milanova was appointed as Chief Commercial Officer at AGIOS PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

the Company appointed Tsveta Milanova as the Company’s Chief Commercial Officer, effective as of January 3, 2023

View on SEC.gov

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-298895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.